Multiple sclerosis, interferon beta-1b and depression A prospective investigation.

Area of Science:

• Neuroscience
• Psychiatry
• Immunology

Background:

• Multiple sclerosis (MS) is a chronic neurological condition.
• Interferon beta-1b is a common treatment for relapsing-remitting MS.
• The relationship between MS treatments and mood disorders requires further investigation.

Purpose of the Study:

• To examine the association between major depression and interferon beta-1b treatment in MS patients.
• To determine if prior psychiatric history or family history of affective illness impacts depression rates post-treatment.

Main Methods:

• Forty-two relapsing-remitting MS patients were assessed for major depression using the Structured Clinical Interview for Axis 1 DSM-IV Disorders.
• Assessments were conducted before and at 3, 6, and 12 months after initiating interferon beta-1b.
• Patients diagnosed with major depression received antidepressant medication.

Main Results:

• Prevalence of major depression was 21.4% at baseline, decreasing to 17.5% at 3 months, 11.4% at 6 months, and 6.3% at 12 months.
• A history of psychiatric illness was significantly associated with major depression.
• Family history of affective disorder did not show a significant association with major depression.

Conclusions:

• Major depression in MS patients treated with interferon beta-1b is linked to pre-existing psychiatric conditions.
• The decline in depression rates suggests positive effects of antidepressant medication and potentially interferon beta-1b on mood.
• Further research is needed to establish causality.